Retrieve available abstracts of 39 articles: HTML format
Single Articles
May 2025
DEV H, Linch M, Narahari K, Milne-Clark T, et al Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the
Effects of Olaparib +/- Degarelix in Primary Prostate Cancer.
Clin Cancer Res. 2025 May 13:OF1-OF11. doi: 10.1158/1078-0432.CCR-24-1304. PubMedAbstract available
ARAFA AT, Yadav S, Marshall CH, Mauer E, et al Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular
Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
Clin Cancer Res. 2025;31:1730-1745. PubMedAbstract available
April 2025
WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al p-AKT protein expression predicts response to AKT inhibitor combined with
docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848. PubMedAbstract available
SHAH K, Secrest MH, Zhou W, Wang S, et al Clinical Context Shapes the Relationship Between Genomic Alterations and Response
to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
Clin Cancer Res. 2025 Apr 14. doi: 10.1158/1078-0432.CCR-24-1812. PubMedAbstract available
KISHAN AU, McGreevy K, Valle L, Steinberg M, et al Validation and Derivation of MicroRNA-based Germline Signatures Predicting
Radiation Toxicity in Prostate Cancer.
Clin Cancer Res. 2025 Apr 7. doi: 10.1158/1078-0432.CCR-24-3951. PubMedAbstract available
March 2025
MCNEVIN CS, Keogh A, Mohammed Nur M, McGovern B, et al Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large
Prospective Cohort.
Clin Cancer Res. 2025 Mar 19:OF1-OF8. doi: 10.1158/1078-0432.CCR-24-1210. PubMedAbstract available
ZHANG L, Teng PC, Cavassani KA, Wang J, et al Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage
Plasticity that Associates with a Clinically Aggressive Subtype of Prostate
Cancer.
Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-3660. PubMedAbstract available
HWANG J, Likasitwatanakul P, Deshmukh SK, Wu S, et al Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate
Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic
Subtypes.
Clin Cancer Res. 2025;31:936-948. PubMedAbstract available
February 2025
BJARTELL A, Krzyzanowska A, Liu VYT, Tierney M, et al Validation of a digital pathology-based multimodal artificial intelligence
biomarker in a prospective, real-world prostate cancer cohort treated with
prostatectomy.
Clin Cancer Res. 2025 Feb 21. doi: 10.1158/1078-0432.CCR-24-3656. PubMedAbstract available
GALSKY MD, Autio KA, Cabanski CR, Wentzel K, et al Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform
Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate
Cancer.
Clin Cancer Res. 2025 Feb 18. doi: 10.1158/1078-0432.CCR-24-3693. PubMedAbstract available
BIDKAR AP, Peter R, Wadhwa A, Bobba KN, et al Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac
Therapy.
Clin Cancer Res. 2025 Feb 13. doi: 10.1158/1078-0432.CCR-24-2850. PubMedAbstract available
January 2025
CHIU CL, Zhang D, Zhao H, Wei Y, et al Targeting AXL inhibits the growth and metastasis of prostate cancer in bone.
Clin Cancer Res. 2025 Jan 29. doi: 10.1158/1078-0432.CCR-24-3028. PubMedAbstract available
ANDREWS J, Kim Y, Horjeti E, Arafa A, et al PSMA+ Extracellular Vesicles are a Biomarker for SABR in Oligorecurrent Prostate
Cancer Analysis from the STOMP-like and ORIOLE trial cohorts.
Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-3027. PubMedAbstract available
WELTI J, Bogdan D, Figueiredo I, Coleman I, et al NXP800 activates the unfolded protein response, altering AR and E2F function to
impact castration-resistant prostate cancer growth.
Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2386. PubMedAbstract available
November 2024
HAFFNER MC, Morris MJ, Ding CC, Sayar E, et al Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate
Cancer Biopsies.
Clin Cancer Res. 2024 Nov 26. doi: 10.1158/1078-0432.CCR-24-2061. PubMedAbstract available
WINQUIST E, Hotte SJ, Chi K, Sridhar S, et al Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients
with Metastatic Castration Resistant Prostate Cancer.
Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1612. PubMedAbstract available
NAWFAL R, El Hajj Chehade R, Berchuck JE Unearthing a prostate cancer cfDNA signature that "stems" from AR alterations.
Clin Cancer Res. 2024 Nov 4. doi: 10.1158/1078-0432.CCR-24-2849. PubMedAbstract available
October 2024
STOPSACK KH, Vijai J, Conry M, Berchuck JE, et al Germline DNA damage repair variants and prognosis of patients with high-risk or
metastatic prostate cancer.
Clin Cancer Res. 2024 Oct 25. doi: 10.1158/1078-0432.CCR-24-2483. PubMedAbstract available
September 2024
ISAACSSON VELHO P, Bastos DA, Saint'ana PT, Rigatti B, et al Nivolumab in patients with metastatic castration-resistant prostate cancer with
and without DNA repair defects.
Clin Cancer Res. 2024 Sep 27. doi: 10.1158/1078-0432.CCR-24-1595. PubMedAbstract available
CHOU J, Robinson TM, Egusa EA, Lodha R, et al Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate
Cancer with PARP Inhibitors.
Clin Cancer Res. 2024 Sep 25. doi: 10.1158/1078-0432.CCR-23-3785. PubMedAbstract available
JENSEN JL, Bobek O, Chan ICC, Miller BC, et al Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant
Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance
A031201).
Clin Cancer Res. 2024 Sep 17:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0803. PubMedAbstract available
DALLOS MC, Obradovic AZ, McCann P, Chowdhury N, et al Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized
Prostate Cancer.
Clin Cancer Res. 2024 Sep 13. doi: 10.1158/1078-0432.CCR-24-0060. PubMedAbstract available
August 2024
CHAUHAN PS, Alahi I, Sinha S, Ledet EM, et al Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness
features associated with worse survival in lethal prostate cancer.
Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-1658. PubMedAbstract available
HUSSAIN M, Kocherginsky M, Agarwal N, Adra N, et al Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic
Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Clin Cancer Res. 2024 Aug 8. doi: 10.1158/1078-0432.CCR-24-1402. PubMedAbstract available
NGUYEN CB, Reimers MA, Perera C, Abida W, et al Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate
Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
Clin Cancer Res. 2024;30:3200-3210. PubMedAbstract available
July 2024
SWEENEY CJ, Petry R, Xu C, Childress M, et al Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in
Metastatic Castration Resistant Prostate Cancer.
Clin Cancer Res. 2024 Jul 11. doi: 10.1158/1078-0432.CCR-24-1096. PubMedAbstract available
LENIS AT, Ravichandran V, Brown S, Alam SM, et al Microsatellite Instability, Tumor Mutational Burden, and Response to Immune
Checkpoint Blockade in Patients with Prostate Cancer.
Clin Cancer Res. 2024 Jul 1. doi: 10.1158/1078-0432.CCR-23-3403. PubMedAbstract available
April 2024
APARICIO AM, Tidwell RSS, Yadav SS, Chen JS, et al A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a
Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate
Cancer.
Clin Cancer Res. 2024 Apr 29. doi: 10.1158/1078-0432.CCR-23-3740. PubMedAbstract available
ARCHER S, Brailey PM, Song M, Bartlett PD, et al CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating
PSMA-Positive Tumors.
Clin Cancer Res. 2024;30:1595-1606. PubMedAbstract available
SCHATZ CA, Zitzmann-Kolbe S, Moen I, Klotz M, et al Preclinical efficacy of a PSMA-targeted actinium-225 conjugate
(225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
Clin Cancer Res. 2024 Apr 9. doi: 10.1158/1078-0432.CCR-23-3746. PubMedAbstract available
CHO H, Byun SS, Son NH, Chung JI, et al Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and
Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer.
Clin Cancer Res. 2024 Apr 8:OF1-OF13. doi: 10.1158/1078-0432.CCR-23-3083. PubMedAbstract available
March 2024
DESAI KB, Serritella AV, Stadler WM, O'Donnell PH, et al A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator
relacorilant in patients with metastatic castration resistant prostate cancer.
Clin Cancer Res. 2024 Mar 27. doi: 10.1158/1078-0432.CCR-23-3636. PubMedAbstract available
AGARWAL N, Castellano D, Alonso-Gordoa T, Arranz Arija JA, et al A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with
Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
Clin Cancer Res. 2024 Mar 21. doi: 10.1158/1078-0432.CCR-23-3436. PubMedAbstract available
ANSELMINO N, Labanca E, Shepherd PDA, Dong J, et al Integrative molecular analyses of the MD Anderson prostate cancer patient-derived
xenograft (MDA PCa PDX) series.
Clin Cancer Res. 2024 Mar 15. doi: 10.1158/1078-0432.CCR-23-2438. PubMedAbstract available
February 2024
VELLKY JE, Kirkpatrick BJ, Gutgesell LC, Morales M, et al ERBB3 overexpression is enriched in diverse patient populations with
castration-sensitive prostate cancer and is associated with a unique AR activity
signature.
Clin Cancer Res. 2024 Feb 2. doi: 10.1158/1078-0432.CCR-23-2161. PubMedAbstract available
DORFF T, Horvath LG, Autio K, Bernard-Tessier A, et al A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific
T-cell engager for metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2024 Feb 1. doi: 10.1158/1078-0432.CCR-23-2978. PubMedAbstract available
January 2024
HALABI S, Guo S, Park JJ, Nanus DM, et al The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic
castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Clin Cancer Res. 2024 Jan 18. doi: 10.1158/1078-0432.CCR-23-3017. PubMedAbstract available
ABIDA W, Hahn AW, Shore N, Agarwal N, et al Phase 1 Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination
with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate
Cancer Progressing on Enzalutamide.
Clin Cancer Res. 2024 Jan 16. doi: 10.1158/1078-0432.CCR-23-3508. PubMedAbstract available
September 2023
CHAUDAGAR K, Hieromnimon HM, Kelley A, Labadie B, et al Suppression of tumor cell lactate-generating signaling pathways eradicates murine
PTEN/p53-deficient aggressive-variant prostate cancer via macrophage
phagocytosis.
Clin Cancer Res. 2023 Sep 18. doi: 10.1158/1078-0432.CCR-23-1441. PubMedAbstract available